No Result
View All Result
  • Login
Saturday, July 25, 2026
theadvisertimes.com
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading
No Result
View All Result
theadvisertimes.com
No Result
View All Result
Home Markets

The $4,200 Ozempic Ransom You Have to Pay Every Year to Keep the Weight Off

by theadvisertimes.com
6 months ago
in Markets
Reading Time: 3 mins read
A A
0
The ,200 Ozempic Ransom You Have to Pay Every Year to Keep the Weight Off
Share on FacebookShare on TwitterShare on LInkedIn


It feels like the weight-loss miracle so many have been waiting for. You watch the transformation videos on TikTok, see the celebrities shrinking before your eyes and hear the stories of friends who have effortlessly dropped 30 pounds.

Ozempic (semaglutide) has become the “Kleenex” of diet culture — a catch-all name for a weekly injection that melts fat without the misery of starvation.

But there’s a major catch. These drugs are not a cure. They are a treatment. Like blood pressure medication, they only work as long as you take them.

And there’s one crucial question every potential user should ask before their first dose: What happens when I stop?

The science of the rebound

Clinical trials paint a sobering picture for both major drug types.

For Ozempic and Wegovy (semaglutide) users, research found that one year after stopping the drug, participants regained two-thirds of their lost weight.

For Zepbound (tirzepatide) users, the news is similar. In a study of the drug, all participants took tirzepatide for 36 weeks and lost significant weight. Researchers then switched a randomized portion of the group to a placebo, at which point they regained 14% of their body weight in the following year, effectively erasing the majority of their progress.

It’s a matter of biology. When you lose weight rapidly, your body fights to get it back. It lowers your metabolism and ramps up your hunger hormones.

These drugs work by suppressing those signals. When you remove the drug, the dam breaks. Your body doesn’t just go back to normal. It often swings hard in the other direction to recover lost fat storage.

The return of ‘food noise’

One of the most praised effects of these drugs is the silencing of “food noise” — that constant mental chatter about what to eat next. For many users, this is the first time in their lives they haven’t felt obsessed with food.

When they stop the medication, that noise comes back, often louder than before.

Obesity specialists have noted that patients don’t just feel hungry; they feel an intense, biological drive to eat that can be overwhelming.

Because they haven’t necessarily built the psychological habits or muscle mass to maintain the weight naturally (since the drug did the heavy lifting), they’re left defenseless against these cravings.

The financial reality of a forever prescription

If you’re taking these drugs for weight loss, you need to budget for them like you would a utility bill.

As of early 2026, the pricing has shifted. While retail prices without insurance still hover near $1,000 per month, manufacturers have introduced new cash-pay options (like Zepbound vials or Wegovy intro offers) that can drop the price to the $199 to $399 range for eligible patients.

However, even at $350 a month, you’re looking at roughly $4,200 a year — indefinitely.

If you rely on insurance, remember that coverage is fickle. Medicare is starting to shift its rules regarding weight loss drugs, but there’s no guarantee of coverage. Other insurance coverage varies.

If you change jobs, lose coverage or your insurer changes their formulary, you could be forced to stop cold turkey and face the risk of regaining weight.

The health whiplash

Beyond the number on the scale, stopping these medications can shock your system.

Blood sugar spikes: If you were using these drugs for Type 2 diabetes or even pre-diabetes, stopping can cause your blood glucose levels to surge. This is dangerous and requires immediate management by a doctor.
Cardiometabolic regression: The clinical trials also found that improvements in cardiometabolic risk factors (like blood pressure and inflammation markers) reverted to baseline once the weight came back. You lose the heart health protection along with the weight.

Is it worth it?

This doesn’t mean you shouldn’t take them. For people with severe obesity or diabetes, these drugs are lifesavers. But you need to shift your mindset.

Don’t view Zepbound or Ozempic as a jumpstart to get skinny for a wedding or a reunion. Think of it instead as a lifetime management tool for a chronic condition.

If you aren’t willing — or financially able — to take it for the long haul, you might be setting yourself up for an expensive, heartbreaking cycle of yo-yo dieting that leaves you heavier than when you started.



Source link

Tags: OzempicPayransomweightyear
ShareTweetShare
Previous Post

ZOOZ provides Israelis with exposure to Bitcoin

Next Post

Where Prediction Markets Fit in Portfolios

Related Posts

Some Costco Shoppers Could Qualify for Cash in Settlement Payout

Some Costco Shoppers Could Qualify for Cash in Settlement Payout

by theadvisertimes.com
July 24, 2026
0

Shoppers in Washington state who received certain promotional emails from Costco over the past five years may be eligible for...

Central Pacific Financial Q2 2026 Earnings Deep Dive: Key Takeaways

Central Pacific Financial Q2 2026 Earnings Deep Dive: Key Takeaways

by theadvisertimes.com
July 24, 2026
0

AlphaStreet Newsdesk powered by AlphaStreet Intelligence Related Coverage Preview Central Pacific Financial (CPF) Q2 2026 Preview: EPS Est. $0.78, Reports...

Moody’s: AI spending threatens credit quality of Amazon, Meta, Alphabet

Moody’s: AI spending threatens credit quality of Amazon, Meta, Alphabet

by theadvisertimes.com
July 24, 2026
0

Sundar Pichai, CEO of Alphabet, Satya Nadella, CEO of Microsoft, Andy Jassy, CEO of Amazon and Mark Zuckerberg, CEO of...

Trader who successfully shorted Tesla into earnings now sets sights on this high flyer

Trader who successfully shorted Tesla into earnings now sets sights on this high flyer

by theadvisertimes.com
July 24, 2026
0

The bearish Tesla set-up we flagged ahead of Wednesday's report has delivered most of what it can. Two ways forward:...

Solving the Distance Bottleneck – Banyan Hill Publishing

Solving the Distance Bottleneck – Banyan Hill Publishing

by theadvisertimes.com
July 24, 2026
0

If you or someone you love ever needs surgery, you’ll obviously want to use the best surgeon available. But what...

Axon – Doing Good While Doing Well

Axon – Doing Good While Doing Well

by theadvisertimes.com
July 24, 2026
0

“Do good while doing well” is the idea that you can invest in good causes while also reaping significant profits....

Next Post
Where Prediction Markets Fit in Portfolios

Where Prediction Markets Fit in Portfolios

Stephen Miller vs ICE Barbie & Corey Is a Distraction From Civil Conflict

Stephen Miller vs ICE Barbie & Corey Is a Distraction From Civil Conflict

  • Trending
  • Comments
  • Latest
SEC pushes private market access, but retail is already in

SEC pushes private market access, but retail is already in

July 16, 2026
How I Maximize My Sapphire Reserve Dining Credit

How I Maximize My Sapphire Reserve Dining Credit

July 10, 2026
Fourth of July 2026 Freebies and Deals

Fourth of July 2026 Freebies and Deals

July 3, 2026
5 things financial therapists want every advisor to know

5 things financial therapists want every advisor to know

June 26, 2026
The Weekly Notable Startup Funding Report: 6/22/26 – AlleyWatch

The Weekly Notable Startup Funding Report: 6/22/26 – AlleyWatch

June 21, 2026
Weekend Reading For Financial Planners (June 27–28)

Weekend Reading For Financial Planners (June 27–28)

June 26, 2026
World’s quietest metal just dropped a huge bullish signal

World’s quietest metal just dropped a huge bullish signal

0
Solving the Distance Bottleneck – Banyan Hill Publishing

Solving the Distance Bottleneck – Banyan Hill Publishing

0
Q1 Results today: SBI Life, Tata Consumer, Hindustan Zinc among 86 companies to announce earnings

Q1 Results today: SBI Life, Tata Consumer, Hindustan Zinc among 86 companies to announce earnings

0
Your Credit Utilization Should Stay Below 30%

Your Credit Utilization Should Stay Below 30%

0
Interventionism and Inequality | Mises Institute

Interventionism and Inequality | Mises Institute

0
Pi Network Price Slips 10% ahead of Token Unlock: Is More Selling Ahead?

Pi Network Price Slips 10% ahead of Token Unlock: Is More Selling Ahead?

0
Pi Network Price Slips 10% ahead of Token Unlock: Is More Selling Ahead?

Pi Network Price Slips 10% ahead of Token Unlock: Is More Selling Ahead?

July 24, 2026
Strategy now publishes the Bitcoin return threshold below which it may have to restructure

Strategy now publishes the Bitcoin return threshold below which it may have to restructure

July 24, 2026
Nearly 150,000 California mail ballots rejected in June primary thanks to late-arriving ballots

Nearly 150,000 California mail ballots rejected in June primary thanks to late-arriving ballots

July 24, 2026
Some Costco Shoppers Could Qualify for Cash in Settlement Payout

Some Costco Shoppers Could Qualify for Cash in Settlement Payout

July 24, 2026
Central Pacific Financial Q2 2026 Earnings Deep Dive: Key Takeaways

Central Pacific Financial Q2 2026 Earnings Deep Dive: Key Takeaways

July 24, 2026
US stocks today: Nasdaq lags on angst over AI spending ahead of earnings reports

US stocks today: Nasdaq lags on angst over AI spending ahead of earnings reports

July 24, 2026
theadvisertimes.com

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Economy
  • Financial Planning
  • Investing
  • Market Analysis
  • Markets
  • Money
  • Personal Finance
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Pi Network Price Slips 10% ahead of Token Unlock: Is More Selling Ahead?
  • Strategy now publishes the Bitcoin return threshold below which it may have to restructure
  • Nearly 150,000 California mail ballots rejected in June primary thanks to late-arriving ballots
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • About Us
  • Contact Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.